<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063073</url>
  </required_header>
  <id_info>
    <org_study_id>224</org_study_id>
    <nct_id>NCT03063073</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block</brief_title>
  <acronym>pec`s</acronym>
  <official_title>Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Patient Undergoing Breast Cancer Surgery :A Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Egypt Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>South Egypt Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Pecs block (pectoral nerves block) is an easy and reliable superficial block inspired by
      the infraclavicular block approach and the intercostal abdominis plane blocks . Many
      additives were used in combination with local anesthetics in Pecs block to prolong the
      postoperative analgesia (fentanyl, dexmedetomidine).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 patients scheduled for modified radical mastectomy surgery under general anesthesia. Group
      I (Bupivacaine group): patients underwent modified radical mastectomy were given preoperative
      ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine divided into 10 ml
      injected between the pectoralis muscles on the interfascial plane, and 20 ml injected between
      the Pectoralis minor muscle and the serratus muscle.Group II (Bupivacaine + Dexmedetomidine
      group) : preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
      plus Dexmedetomidine (1 µg/kg) divided into 20 ml injected between the pectoralis muscles on
      the interfascial plane , and 10 ml injected between the Pectoralis minor muscle and the
      serratus muscle.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 25, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2017</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>I.V patient controlled analgesia (PCA) morphine consumption</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>the total dose of I.V patient controlled analgesia (PCA) morphine consumption in the first 48 hours postoperative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain relief</measure>
    <time_frame>48 hour</time_frame>
    <description>by visual analogue scale measurement</description>
  </secondary_outcome>
  <other_outcome>
    <measure>stress response</measure>
    <time_frame>24 hour</time_frame>
    <description>Three Blood samples were collected from each patient for detection of cortisol &amp; prolactin levels, the first was preoperative, the second and the third were 1h and 24 h postoperatively</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Group I (Bupivacaine group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ultrasound guided modified Pec`s block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine Injection [Precedex]</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection [Precedex] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injection [Precedex]</intervention_name>
    <description>ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection [Precedex]</description>
    <arm_group_label>Dexmedetomidine Injection [Precedex]</arm_group_label>
    <other_name>[Precedex]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>Group I (Bupivacaine group)</arm_group_label>
    <arm_group_label>Dexmedetomidine Injection [Precedex]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I - II patients

               -  weight 50- 100 kg

          -  age 18-60 years

        Exclusion Criteria:

          -  History of bleeding diathesis

          -  Relevant drug allergy

          -  Opioid dependence

          -  Sepsis

          -  Those with psychiatric illnesses that would interfere with perception and assessment
             of pain will be excluded from the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>sahar m abd elbaqy, professor</last_name>
    <role>Study Director</role>
    <affiliation>manager</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mohammed f abd elhamed, ass.lecturer</last_name>
    <phone>01015249890</phone>
    <email>m.farghaly.na@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>mohammad f mohammad, lecturer</last_name>
    <phone>01093942354</phone>
    <email>mfaroukma@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South EGYPT cancer institute</name>
      <address>
        <city>Assuit</city>
        <zip>088</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esam m el sharkawy, prof.</last_name>
      <phone>0882332016</phone>
      <email>sru@seci.info</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South Egypt Cancer Institute</investigator_affiliation>
    <investigator_full_name>Mohammed Farghaly Abd El hamid Ahmed</investigator_full_name>
    <investigator_title>assisstant lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

